ADVISORSHARES PURE US CANNABIS ETF INCREASES BY 20%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy TLRY?
Source: moomoo
Advisors Share Insights: Advisors are providing insights on the cannabis market, focusing on investment opportunities and trends.
Pursue US Cannabis ETF: There is a growing interest in establishing a US-based cannabis exchange-traded fund (ETF) to capitalize on the expanding market.
Market Growth Potential: The cannabis industry is projected to grow significantly, with estimates suggesting a potential 20% increase in market value.
Investment Strategies: Advisors are discussing various investment strategies to navigate the complexities of the cannabis sector effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 5.900
Low
8.50
Averages
9.57
High
10.00
Current: 5.900
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. It operates through four segments: cannabis operations, beverage operations, distribution operations, and the wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The beverage operations, which encompasses the production, marketing and of beverage products. The distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers. The Wellness products, which encompasses wellness and better-for-you foods and beverages. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, Chowie Wowie and others. It supports over 40 brands in over 20 countries, including cannabis offerings, hemp-based foods and craft beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Stock Volatility Amid Regulatory Developments
- Stock Volatility: Tilray's stock briefly surged from around $7 to $8 on April 22 due to the U.S. Department of Justice's plans to reschedule marijuana, but quickly fell back to nearly $6, indicating the market's sensitivity to regulatory news.
- Regulatory Developments: While rescheduling moves marijuana from Schedule I to Schedule III, it does not immediately open the U.S. market for companies like Tilray, reflecting a cautious market sentiment regarding the implications of this announcement.
- Tax Implications: The rescheduling will exempt Tilray and other cannabis companies from Section 280E tax rules, allowing for regular expense deductions; however, full legalization remains essential for significant business growth, and current regulatory progress is slow.
- Market Outlook: Given the slow regulatory advancements and Tilray's ongoing losses, analysts recommend investors remain on the sidelines with this risky growth stock, especially considering the poor performance of Tilray's cannabis-infused beverages, which could continue to weigh on share prices.
See More
Marijuana Stocks Surge Then Fall Back
- Short-Lived Surge: Tilray Brands' stock price briefly rose from around $7 to $8 on April 22 due to the DOJ's plans to reschedule marijuana, but quickly fell back to approximately $6, indicating significant market volatility.
- Market Reaction: The spike is seen as a classic case of 'buy the rumor, sell the news,' as the market shifted from bullish to bearish, reflecting investor caution regarding the cannabis industry's future prospects.
- Rescheduling Impact: While rescheduling moves marijuana from Schedule I to Schedule III, aligning it with prescription drugs, this change alone won't benefit companies like Tilray without full legalization, as the current rescheduling only applies to FDA-approved medical products.
- Company Challenges: Tilray continues to face persistent losses and poor performance in its cannabis-infused beverages, and while rescheduling could offer tax relief, the slow regulatory progress necessitates a cautious approach for investors considering this high-risk growth stock.
See More
Tilray Stock Surges Briefly on Marijuana Rescheduling News
- Brief Price Surge: Tilray's stock experienced a brief surge on April 22 due to the DOJ's plans to reschedule marijuana products from Schedule I to Schedule III, rising from around $7 to $8 per share, but quickly fell back to near $6, indicating significant market volatility.
- Limitations of Rescheduling: The rescheduling only applies to FDA-approved medical marijuana products, with full rescheduling pending an administrative hearing process, leading to a swift bearish market reaction to the news.
- Tax Implications: If marijuana is fully rescheduled to Schedule III, Tilray and its peers would no longer be subject to Section 280E tax rules, allowing for regular expense deductions, which could improve financial conditions, but broader federal legalization is still needed.
- Cautious Investment Advice: Given the slow regulatory progress and Tilray's ongoing losses, analysts recommend investors remain on the sidelines with this risky growth stock, especially as Tilray's product performance has been poor and it did not make the list of top investment stocks.
See More
U.S. Reschedules Medical Marijuana to Schedule III, Impact on Cannabis Industry
- Industry Milestone: The U.S. government's rescheduling of medical marijuana to Schedule III marks a significant advancement for the industry, acknowledging valid medical uses and expected to benefit many cannabis companies in the U.S.
- Rescheduling vs. Legalization: Investors must note that rescheduling does not equate to legalization; while it facilitates research, marijuana remains a controlled substance and federally illegal, particularly for recreational use, which has not been rescheduled yet.
- Tilray's Market Positioning: Tilray Brands highlighted its readiness for U.S. expansion in a press release, calling the rescheduling a 'defining inflection point,' although the actual opportunity to enter the U.S. market remains uncertain and could take years to materialize.
- Investment Risk Warning: Despite investor hopes for U.S. legalization, Tilray's stock has underperformed in recent years, failing to generate positive returns since 2018, prompting investors to adopt a wait-and-see approach to mitigate excessive risk.
See More
Tilray Brands Seizes Opportunities in U.S. Medical Marijuana Market
- Market Opportunities and Challenges: Tilray Brands believes it is well-positioned in the U.S. medical marijuana market, although changes in U.S. laws could take years to materialize, and there is currently no indication that lawmakers are focused on this issue.
- Impact of Rescheduling: The U.S. government has rescheduled medical marijuana from a Schedule I to a Schedule III substance, marking a milestone that brings positive signals for the industry, indicating valid medical uses for marijuana, which many U.S. cannabis companies will benefit from.
- Cautious Investor Sentiment: While Tilray Brands referred to this as a
See More
U.S. Reschedules Medical Marijuana to Schedule III: Implications for the Industry
- Industry Milestone: The U.S. government's rescheduling of medical marijuana to Schedule III acknowledges its valid medical uses, which is expected to benefit many cannabis companies in the U.S., although it does not equate to legalization.
- Market Access Barriers: While Tilray Brands claims it is 'positioned for U.S. expansion,' the rescheduling does not open the border for Canadian producers to move products south, as federal laws still restrict access, making market entry unlikely in the near term.
- Investment Risk Warning: Investors should be cautious, as hopes based on government reform have often led to significant losses; Tilray has not generated a positive annual return since 2018, highlighting the gap between market expectations and reality regarding legalization.
- Cautious Investment Advice: Given the current situation, Tilray's stock is viewed as too risky, and investors are advised to adopt a wait-and-see approach, especially as other more promising investment opportunities arise.
See More
Tilray Stock Volatility Amid Regulatory Developments
- Stock Volatility: Tilray's stock briefly surged from around $7 to $8 on April 22 due to the U.S. Department of Justice's plans to reschedule marijuana, but quickly fell back to nearly $6, indicating the market's sensitivity to regulatory news.
- Regulatory Developments: While rescheduling moves marijuana from Schedule I to Schedule III, it does not immediately open the U.S. market for companies like Tilray, reflecting a cautious market sentiment regarding the implications of this announcement.
- Tax Implications: The rescheduling will exempt Tilray and other cannabis companies from Section 280E tax rules, allowing for regular expense deductions; however, full legalization remains essential for significant business growth, and current regulatory progress is slow.
- Market Outlook: Given the slow regulatory advancements and Tilray's ongoing losses, analysts recommend investors remain on the sidelines with this risky growth stock, especially considering the poor performance of Tilray's cannabis-infused beverages, which could continue to weigh on share prices.
See More
Marijuana Stocks Surge Then Fall Back
- Short-Lived Surge: Tilray Brands' stock price briefly rose from around $7 to $8 on April 22 due to the DOJ's plans to reschedule marijuana, but quickly fell back to approximately $6, indicating significant market volatility.
- Market Reaction: The spike is seen as a classic case of 'buy the rumor, sell the news,' as the market shifted from bullish to bearish, reflecting investor caution regarding the cannabis industry's future prospects.
- Rescheduling Impact: While rescheduling moves marijuana from Schedule I to Schedule III, aligning it with prescription drugs, this change alone won't benefit companies like Tilray without full legalization, as the current rescheduling only applies to FDA-approved medical products.
- Company Challenges: Tilray continues to face persistent losses and poor performance in its cannabis-infused beverages, and while rescheduling could offer tax relief, the slow regulatory progress necessitates a cautious approach for investors considering this high-risk growth stock.
See More
Tilray Stock Surges Briefly on Marijuana Rescheduling News
- Brief Price Surge: Tilray's stock experienced a brief surge on April 22 due to the DOJ's plans to reschedule marijuana products from Schedule I to Schedule III, rising from around $7 to $8 per share, but quickly fell back to near $6, indicating significant market volatility.
- Limitations of Rescheduling: The rescheduling only applies to FDA-approved medical marijuana products, with full rescheduling pending an administrative hearing process, leading to a swift bearish market reaction to the news.
- Tax Implications: If marijuana is fully rescheduled to Schedule III, Tilray and its peers would no longer be subject to Section 280E tax rules, allowing for regular expense deductions, which could improve financial conditions, but broader federal legalization is still needed.
- Cautious Investment Advice: Given the slow regulatory progress and Tilray's ongoing losses, analysts recommend investors remain on the sidelines with this risky growth stock, especially as Tilray's product performance has been poor and it did not make the list of top investment stocks.
See More
U.S. Reschedules Medical Marijuana to Schedule III, Impact on Cannabis Industry
- Industry Milestone: The U.S. government's rescheduling of medical marijuana to Schedule III marks a significant advancement for the industry, acknowledging valid medical uses and expected to benefit many cannabis companies in the U.S.
- Rescheduling vs. Legalization: Investors must note that rescheduling does not equate to legalization; while it facilitates research, marijuana remains a controlled substance and federally illegal, particularly for recreational use, which has not been rescheduled yet.
- Tilray's Market Positioning: Tilray Brands highlighted its readiness for U.S. expansion in a press release, calling the rescheduling a 'defining inflection point,' although the actual opportunity to enter the U.S. market remains uncertain and could take years to materialize.
- Investment Risk Warning: Despite investor hopes for U.S. legalization, Tilray's stock has underperformed in recent years, failing to generate positive returns since 2018, prompting investors to adopt a wait-and-see approach to mitigate excessive risk.
See More
Tilray Brands Seizes Opportunities in U.S. Medical Marijuana Market
- Market Opportunities and Challenges: Tilray Brands believes it is well-positioned in the U.S. medical marijuana market, although changes in U.S. laws could take years to materialize, and there is currently no indication that lawmakers are focused on this issue.
- Impact of Rescheduling: The U.S. government has rescheduled medical marijuana from a Schedule I to a Schedule III substance, marking a milestone that brings positive signals for the industry, indicating valid medical uses for marijuana, which many U.S. cannabis companies will benefit from.
- Cautious Investor Sentiment: While Tilray Brands referred to this as a
See More
U.S. Reschedules Medical Marijuana to Schedule III: Implications for the Industry
- Industry Milestone: The U.S. government's rescheduling of medical marijuana to Schedule III acknowledges its valid medical uses, which is expected to benefit many cannabis companies in the U.S., although it does not equate to legalization.
- Market Access Barriers: While Tilray Brands claims it is 'positioned for U.S. expansion,' the rescheduling does not open the border for Canadian producers to move products south, as federal laws still restrict access, making market entry unlikely in the near term.
- Investment Risk Warning: Investors should be cautious, as hopes based on government reform have often led to significant losses; Tilray has not generated a positive annual return since 2018, highlighting the gap between market expectations and reality regarding legalization.
- Cautious Investment Advice: Given the current situation, Tilray's stock is viewed as too risky, and investors are advised to adopt a wait-and-see approach, especially as other more promising investment opportunities arise.
See More
